These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21773752)

  • 1. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
    Ohata Y; Tomita Y; Nakayama M; Tamura K; Tanigawara Y
    J Infect Chemother; 2011 Dec; 17(6):831-41. PubMed ID: 21773752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
    Ikawa K; Morikawa N; Ohge H; Ikeda K; Sueda T; Taniwaki M; Kurisu K
    J Infect Chemother; 2010 Feb; 16(1):25-32. PubMed ID: 20082106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.
    Ohata Y; Tomita Y; Nakayama M; Kozuki T; Sunakawa K; Tanigawara Y
    Drug Metab Pharmacokinet; 2011; 26(5):523-31. PubMed ID: 21747200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
    Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
    Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
    Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
    Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
    Lee DG; Choi SM; Shin WS; Lah HO; Yim DS
    Int J Antimicrob Agents; 2006 Oct; 28(4):333-9. PubMed ID: 16942864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
    Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
    Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
    Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
    Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
    J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
    Nomura K; Morikawa N; Ikawa K; Ikeda K; Fujimoto Y; Shimizu D; Taniguchi K; Shimura K; Kanbayashi Y; Komori T; Matsumoto Y; Fujita N; Shimazaki C; Taniwaki M
    J Antimicrob Chemother; 2008 Apr; 61(4):892-900. PubMed ID: 18276604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
    Lomaestro BM; Drusano GL
    Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.